Sristy Kumari

Centre for Dermatology

VV Biotech has discovered a drug that contains RNA and by using this drug the pathway associated with autoimmune skin diseases can be down regulated.

We hypothesize that quantification of target gene miRNA expression in genes may be useful. It also can be a non-invasive approach to monitor the disease activity as well as treatment response of all autoimmune skin diseases.

There are about 1500 distinct skin diseases and few more variants that could be found in an average 15% population related to skin problems. Moreover, it is said that 50 to 75% of individuals may have skin problems at any time in their lives.

We are trying to down regulate pathways associated with interleukins, interferon, and cytokines based on our studies. The targets we have studied includes- IL17, 17A, IL-1,2,4,5,6,12,22,23,33, TLR-6,7,8,9, CD20,40, 151, IFNα, IFNϒ, TNFα, NFkβ, MMP-9,13, CDK-N1α, CDK-1β, and CDKN2A.

These specific pathways could serve as drug targets for chronic and acute skin fibrosis conditions.

Significant diseases- Psoriasis, Lupus of the skin, Morphea/Scleroderma, Eczemas burn, Bechet’s disease, Lichen planus, Dermatomyositis, Pemphigoid.

Systematic therapies- Immunomodulators, and a few novel injectable products.